Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a class action lawsuit against Picard Medical Inc. and several associated defendants for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements and a pump-and-dump scheme that affected the company's stock price during a specified period [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Northern District of California under the case name Louie v. Picard Medical, Inc. et al., asserting claims on behalf of all individuals and entities who purchased Picard Medical Securities (PMI) between September 2, 2025, and October 31, 2025 [1]. - The lead plaintiff deadline for this action is set for April 13, 2026, and individuals wishing to serve as lead plaintiff must file a motion by this date [2][7]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about Picard Medical's business and operations [4]. - It is claimed that the defendants orchestrated a pump-and-dump scheme, where the stock price was artificially inflated through a social media promotion scheme involving impersonators posing as legitimate financial advisors [4]. Group 3: Company Overview - Picard Medical is involved in the design, manufacturing, production, supply, marketing, and sale of medical device products, with its most significant product being an artificial heart called "SynCardia TAH" [3]. - The company is headquartered in Tucson, Arizona, and operates in the United States, Europe, and China [3].

Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a securities class action lawsuit against Picard Medical Inc. due to allegations of a fraudulent stock promotion scheme that led to a significant drop in the company's stock price following an artificial inflation period [1] Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Northern District of California, asserting claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 [1] - The class period for the lawsuit is defined as September 2, 2025, to October 31, 2025, during which investors purchased Picard Medical Securities [1] - The lead plaintiff deadline for this action is set for April 13, 2026 [1] Group 2: Allegations Against Defendants - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about Picard Medical's business and operations [1] - It is claimed that the defendants orchestrated a pump-and-dump scheme, where the stock price was artificially inflated through a social media promotion scheme [1] - Reports indicate that impersonators posing as legitimate financial advisors promoted Picard Medical in online forums, leading to a buying frenzy among retail investors [1] Group 3: Company Overview - Picard Medical Inc. is involved in the design, manufacturing, production, supply, marketing, and sale of medical device products, with its flagship product being an artificial heart called "SynCardia TAH" [1] - The company is headquartered in Tucson, Arizona, and operates in the United States, Europe, and China [1]

Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a class action lawsuit against Picard Medical Inc. and several associated defendants, alleging violations of the Securities Exchange Act due to misleading statements and a fraudulent stock promotion scheme that led to significant losses for investors [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Northern District of California under the case name Louie v. Picard Medical, Inc. et al., with a lead plaintiff deadline set for April 3, 2026 [1][5]. - The class action targets individuals and entities that purchased Picard Medical Securities (PMI) between September 2, 2025, and October 31, 2025, who suffered damages as a result [1][4]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants made materially false and misleading statements and failed to disclose adverse facts about Picard Medical's business and operations [3]. - It is claimed that the defendants orchestrated a "pump-and-dump" scheme, where the stock price was artificially inflated through a social media promotion involving impersonators posing as legitimate financial advisors [2][3]. Group 3: Company Overview - Picard Medical is involved in the design, manufacturing, and sale of medical devices, with its flagship product being the artificial heart "SynCardia TAH" [2]. - The company is headquartered in Tucson, Arizona, and operates in the United States, Europe, and China [2].